PE20151083A1 - Compuestos dimericos - Google Patents
Compuestos dimericosInfo
- Publication number
- PE20151083A1 PE20151083A1 PE2015000907A PE2015000907A PE20151083A1 PE 20151083 A1 PE20151083 A1 PE 20151083A1 PE 2015000907 A PE2015000907 A PE 2015000907A PE 2015000907 A PE2015000907 A PE 2015000907A PE 20151083 A1 PE20151083 A1 PE 20151083A1
- Authority
- PE
- Peru
- Prior art keywords
- optionally substituted
- alkyl
- formula
- aryl
- cyano
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Epidemiology (AREA)
Abstract
Se refiere a un compuesto dimerico de formula I o una sal farmaceuticamente aceptable del mismo, caracterizado porque Z es: (a) arilo opcionalmente sustituido con alcoxi C1-6, halogeno y alquilo C1-6; o (b) heteroarilo opcionalmente sustituido con arilo opcionalmente sustituido con ciano; X es alquilo C1-6, arilo opcionalmente sustituido con alquilo C1-6, heteroarilo, entre otros; Q es un resto de formula A o formula B; R1 es H o ciano; y R2 es alquilo C1-6 opcionalmente sustituido con arilo, cicloalquilo C3-7 opcionalmente fusionado con fenilo, fenilo o cicloalquilarilo C3-7. Dichos compuestos actuan como inhibidores de la union de la proteina SMAC a proteinas inhibidoras de apoptosis (PIA) y/o como inhibidores de la union de la proteina caspasa activada a las PIA, por lo cual resultan utiles en el tratamiento o control del cancer, especialmente de tumores solidos
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261735684P | 2012-12-11 | 2012-12-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20151083A1 true PE20151083A1 (es) | 2015-08-06 |
Family
ID=49726780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2015000907A PE20151083A1 (es) | 2012-12-11 | 2013-12-09 | Compuestos dimericos |
Country Status (19)
Country | Link |
---|---|
US (1) | US9409888B2 (es) |
EP (1) | EP2931719B1 (es) |
JP (1) | JP6309536B2 (es) |
KR (1) | KR20150093228A (es) |
CN (1) | CN104854100B (es) |
AU (1) | AU2013357493A1 (es) |
CA (1) | CA2887497A1 (es) |
CL (1) | CL2015001374A1 (es) |
CO (1) | CO7350640A2 (es) |
CR (1) | CR20150211A (es) |
EA (1) | EA201591024A1 (es) |
HK (1) | HK1213543A1 (es) |
IL (1) | IL238968A0 (es) |
MA (1) | MA38240B1 (es) |
MX (1) | MX2015007053A (es) |
PE (1) | PE20151083A1 (es) |
PH (1) | PH12015501088A1 (es) |
SG (1) | SG11201503718QA (es) |
WO (1) | WO2014090709A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲mPGES-1抑制劑之三唑酮化合物 |
CN104470940B (zh) * | 2012-09-19 | 2018-10-16 | 霍夫曼-拉罗奇有限公司 | 2-氧代-2,3,4,5-四氢-1H-苯并[b][1,4]二氮杂*及其治疗癌症的用途 |
WO2015071393A1 (en) * | 2013-11-18 | 2015-05-21 | F. Hoffmann-La Roche Ag | Tetrahydro-benzodiazepinones |
WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
WO2017056501A1 (ja) * | 2015-10-02 | 2017-04-06 | 日本ゼオン株式会社 | 酸ハライド溶液の製造方法、混合溶液、及びモノエステル化合物の製造方法 |
JP2019514878A (ja) | 2016-04-20 | 2019-06-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Ripk2阻害剤を含むコンジュゲート |
PL3458101T3 (pl) | 2016-05-20 | 2021-05-31 | F. Hoffmann-La Roche Ag | Koniugaty PROTAC-przeciwciało i sposoby ich stosowania |
WO2023031801A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Bifunctional degraders comprising a tead binder |
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI404537B (zh) * | 2005-08-19 | 2013-08-11 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯 |
ES2428896T3 (es) * | 2007-11-16 | 2013-11-12 | Ube Industries, Ltd. | Compuesto de benzacepinona |
WO2009136290A1 (en) * | 2008-05-05 | 2009-11-12 | Aegera Therapeutics, Inc. | Functionalized pyrrolidines and use thereof as iap inhibitors |
EP2784076A1 (en) * | 2009-10-28 | 2014-10-01 | Joyant Pharmaceuticals, Inc. | Dimeric SMAC mimetics |
CN104470940B (zh) * | 2012-09-19 | 2018-10-16 | 霍夫曼-拉罗奇有限公司 | 2-氧代-2,3,4,5-四氢-1H-苯并[b][1,4]二氮杂*及其治疗癌症的用途 |
-
2013
- 2013-12-09 SG SG11201503718QA patent/SG11201503718QA/en unknown
- 2013-12-09 JP JP2015546960A patent/JP6309536B2/ja not_active Expired - Fee Related
- 2013-12-09 KR KR1020157018397A patent/KR20150093228A/ko not_active Application Discontinuation
- 2013-12-09 WO PCT/EP2013/075874 patent/WO2014090709A1/en active Application Filing
- 2013-12-09 US US14/648,282 patent/US9409888B2/en not_active Expired - Fee Related
- 2013-12-09 EA EA201591024A patent/EA201591024A1/ru unknown
- 2013-12-09 EP EP13802359.3A patent/EP2931719B1/en not_active Not-in-force
- 2013-12-09 PE PE2015000907A patent/PE20151083A1/es not_active Application Discontinuation
- 2013-12-09 CA CA 2887497 patent/CA2887497A1/en not_active Abandoned
- 2013-12-09 MA MA38240A patent/MA38240B1/fr unknown
- 2013-12-09 MX MX2015007053A patent/MX2015007053A/es unknown
- 2013-12-09 AU AU2013357493A patent/AU2013357493A1/en not_active Abandoned
- 2013-12-09 CN CN201380064764.0A patent/CN104854100B/zh not_active Expired - Fee Related
-
2015
- 2015-04-17 CO CO15086489A patent/CO7350640A2/es unknown
- 2015-04-22 CR CR20150211A patent/CR20150211A/es unknown
- 2015-05-15 PH PH12015501088A patent/PH12015501088A1/en unknown
- 2015-05-20 CL CL2015001374A patent/CL2015001374A1/es unknown
- 2015-05-21 IL IL238968A patent/IL238968A0/en unknown
-
2016
- 2016-02-05 HK HK16101392.4A patent/HK1213543A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HK1213543A1 (zh) | 2016-07-08 |
PH12015501088A1 (en) | 2015-08-03 |
EA201591024A1 (ru) | 2015-09-30 |
AU2013357493A1 (en) | 2015-04-30 |
CN104854100B (zh) | 2017-05-24 |
MA38240B1 (fr) | 2018-09-28 |
US20160024055A1 (en) | 2016-01-28 |
SG11201503718QA (en) | 2015-06-29 |
CL2015001374A1 (es) | 2015-09-25 |
EP2931719B1 (en) | 2017-01-25 |
JP2016502986A (ja) | 2016-02-01 |
US9409888B2 (en) | 2016-08-09 |
MX2015007053A (es) | 2015-09-28 |
EP2931719A1 (en) | 2015-10-21 |
IL238968A0 (en) | 2015-07-30 |
CA2887497A1 (en) | 2014-06-19 |
WO2014090709A1 (en) | 2014-06-19 |
CR20150211A (es) | 2015-05-29 |
CN104854100A (zh) | 2015-08-19 |
CO7350640A2 (es) | 2015-08-10 |
KR20150093228A (ko) | 2015-08-17 |
JP6309536B2 (ja) | 2018-04-11 |
MA38240A1 (fr) | 2018-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20151083A1 (es) | Compuestos dimericos | |
CY2022004I2 (el) | Συγχωνευμενες ετεροκυκλικες ενωσεις ως αναστολεις πρωτεϊνικης κινασης | |
CY1124469T1 (el) | Παραγωγα πυριμιδινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων | |
UY34570A (es) | Combinaciones de compuestos inhibidores de la proteína ns5a en el virus de hepatitis c | |
NI201600152A (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4 | |
PE20170331A1 (es) | Derivados quinolina como inhibidores smo | |
CL2016001733A1 (es) | Compuestos intermediarios para la preparación de compuestos derivados de piperidinona como inhibidores mdm2 para el tratamiento de cáncer div. sol. 3415-12. | |
DOP2011000204A (es) | Inhibidores de proteina cinasa | |
EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
EA202090516A3 (ru) | Бициклические гетероциклы в качестве ингибиторов fgfr | |
AR094918A1 (es) | Compuestos de tetrahidropirrolotiazina como inhibidores de bace | |
AR082799A1 (es) | Derivados de quinolina y quinoxalina como inhibidores de quinasa | |
PE20161073A1 (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
AR101367A1 (es) | Pirimidinonas como inhibidores del factor xia | |
CL2014000905A1 (es) | Compuestos derivados de acidos carboxilicos de carbamoil-hidroisoquinolinas sustituidas, inhibidores de proteinas antiapoptoticas bcl-xl; composicion farmaceutica; metodo de tratamiento para el cancer de mama, cancer de cuello uterino, cancer colorrectal, cancer hepatocelular, cancer de esofago, leucemias, mielomas, entre otros. | |
GT201400057A (es) | 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante | |
EA201591745A1 (ru) | 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантого idh | |
PE20141855A1 (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
EA201400735A1 (ru) | Производные альфа-амино бороновой кислоты, селективные ингибиторы иммунопротеасомы | |
EA201591753A1 (ru) | 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh | |
EA201370211A1 (ru) | Ингибиторы протеинкиназы | |
EA201591728A1 (ru) | Гетероциклические соединения и способы их применения | |
AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
AR097866A1 (es) | Derivados de 4-azaindol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |